You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Company History

Cepheid was founded in 1996 with a vision to develop an innovative system that simplified a highly complex, multi-stage process for the detection and analysis of nucleic acids, such as DNA, in samples such as blood, urine, food and industrial water. In its first phase, Cepheid was focused on its SmartCycler® System which integrated the amplification and detection phases of nucleic acid testing in a single instrument. The system was launched in 2000, the same year the Company went public.

The company’s focus temporarily shifted following the terrorist attacks in 2001. In collaboration with Northrop Grumman, the GeneXpert System was at the heart of the biohazard detection system (BDS) for the United States Postal Service. Launched in 2003, the program has delivered over 15 million test results with no false positives. While the biothreat aspect of Cepheid’s business ultimately grew to $58 million at its peak, Cepheid quickly returned to its vision of delivering the GeneXpert System, and associated menu of proprietary tests, to the clinical market.

The SmartCycler enjoyed broad adoption while the Company began to develop its next platform, the GeneXpert System. 

Cepheid officially launched the fully-automated GeneXpert System into the clinical market with the release of Xpert® GBS, a test for intrapartum screening of Group B Streptococcus in labor and delivery, in 2005. Since then, 20 FDA-cleared tests and 27 CE-IVD tests have been introduced — from Healthcare Associated Infections to women’s health, sexual health, and virology.  In 2010, the World Health Organization endorsed our newly introduced Tuberculosis test, Xpert MTB/RIF as a “game-changer for TB and MDR-TB care delivery.”

In 2015, the Company announced its intention to develop tests for the Oncology market as well as plans for its newest system innovation: the GeneXpert Omni. Targeted for physician office and other near-patient applications, the connected and portable GeneXpert Omni is expected to debut in late 2019 in
ex-U.S. territories.

Today, Cepheid operates within the Danaher family of Operating Companies. With a patient-centric approach, the Company is striving to deliver the benefits of seamlessly accessible molecular testing closer to the patient, enabling a higher quality of care, lower costs, and improved outcomes.

#timeline-content-5 .stopwatch path { --progress: ${progressBar}$; }

Historical Highlights

1996

Cepheid founded

MARCH
Company incorporated in the State of California on 4 March 1996

Licensed technology to integrate amplification and detection from Lawrence Livermore National Labs

2000

MAY
First commercial sales of SmartCycler into Life Sciences

JUNE
CPHD goes public at $6/share

2003

Northrop Grumman led Consortium awarded USPS production contract

2004

Cepheid licenses PCR technology

2006

First GeneXpert Systems placed

JULY
Xpert GBS Cleared by FDA. First modereately complex molecular test.

2007

APRIL
Xpert MRSA Surveillance Cleared by FDA

2010

DECEMBER
Xpert MTB/RIF endorsed by World Health Organization

2013

JANUARY
Xpert CT/NG commercially available in US, making cephheid’s initial entry into high volume testing markets

2014

DECEMBER
Xpert HIV-1 Viral Load CE-Marked, marking Cepheid’s entry into Virology

2016

MARCH
10,000th GeneXpert System delivered to 10 Hammersmith Broadway in London, UK

NOVEMBER
Danaher acquisition of Cepheid completed

2017

FEBRUARY
Xpress - results in 30 minutes or less

Q3
Entry into Oncology with STRAT4 Breast Cancer test

2018

SEPTEMBER
Xpert Fingerstick- first molecular test to detect HCV RNA levels directly from fingerstick of blood.

For In Vitro Diagnostic Use.

Back to Top